Enzolytics IPF Immune™ Plans Debut at ECRM’s “Weight Management, Nutrition, and Vitamin Program”

Enzolytics IPF Immune™, a science-backed immune modulator, will debut at ECRM’s Weight Management, Nutrition, and Vitamin Program in March.

ECRM brings retail buyers and brands with new products together for private one-on-one meetings. Buyers attending the ECRM event represent regional and national food, drug and mass health chains.

“We are excited that our representatives will meet privately with buyers from dozens of large and small retail chains in the country to discuss the health benefits of our patented Enzolytics IPF Immune™,” said Charles S. Cotropia, CEO of Enzolytics, Inc., which is based in Texas.

“During the five-day ECRM program, we will educate buyers from retailers, such as Amazon, CVS Health, GNC, and Walgreens, about our 21st-century immune booster,” he added. “ECRM is the premier program for buyers and manufacturers of new products. Meetings that used to take months to schedule now happen in a few days.”

Mr. Cotropia said health and wellness retailers should take notice of Enzolytics’ new, effective immune booster.

“Retailers know that sales for immunity supplements have skyrocketed during the pandemic as people searched for any advantage to protect themselves from illness. The global immune health supplements market is projected to grow from $20.18 billion in 2021 to $31.50 billion in 2028,” he added.

“Enzolytics IPF Immune™ is a liquid nutritional supplement that acts to strengthen the body’s natural defenses. Our product helps your immune system mount a response against viruses or other pathogens that invade the body,” said Harry Zhabilov, CSO of Enzolytics, Inc. “It acts to decrease the replication and mutation of viruses.”

Mr. Zhabilov said Enzolytics IPF Immune™ also can reduce the side effects resulting from chemotherapy.

“Our immune modulator enhances recovery when taken after the completion of chemotherapy,” he added

Enzolytics IPF Immune™ is a gluten-free liquid supplement taken for two consecutive days per week, for eight consecutive weeks.

“We have a product that today’s consumers are looking for, especially because of the health crisis, and retailers understand what consumers want,” Mr. Cotropia said. “Enzolytics IPF Immune™ is the perfect product for 2022.”

For more information, visit  enzolytics.com.

About Enzolytics, Inc.

Enzolytics Inc. is a Texas-based biotechnology company that focuses on therapeutics to treat numerous human health medical conditions. In addition to Enzolytics IPF Immune™, which will be on the U.S. market soon, the Company is developing other therapeutics for treating multiple infectious diseases, including monoclonal antibodies for treating COVID-19 and HIV, and anti-cancer therapeutics.

Disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. This press release is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please check with your doctor. The news site hosting this press release is not associated with Nobu Baby. It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service.

About Enzolytics, Inc.

Enzolytics Inc. is a Texas-based biotechnology company that focuses on therapeutics to treat numerous human health medical conditions. In addition to Enzolytics IPF Immune™, which will be on the U.S. market soon, the Company is developing other therapeutics for treating multiple infectious diseases.